Paper30167331
CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion.
Preusser M and 7 others. ESMO Open, 2018. Cited by 36 papers, by iCite.
Cite this record
ConductScience Library. CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. Papers, record 30167331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30167331
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 30962965 | Correction: CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. | https://conductscience.org/library/papers/30962965 |
Source PubMed
References54
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26560360 | Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. | Sci Transl Med | 2015 | https://conductscience.org/library/papers/26560360 | PubMed |
| 2 | 27406875 | Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies. | Endocr Relat Cancer | 2016 | https://conductscience.org/library/papers/27406875 | PubMed |
| 3 | 24011769 | Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer. | Breast | 2013 | https://conductscience.org/library/papers/24011769 | PubMed |
| 4 | 25633797 | The history and future of targeting cyclin-dependent kinases in cancer therapy. | Nat Rev Drug Discov | 2015 | https://conductscience.org/library/papers/25633797 | PubMed |
| 5 | 28327998 | 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). | Ann Oncol | 2017 | https://conductscience.org/library/papers/28327998 | PubMed |
| 6 | 8137296 | Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. | Cancer Res | 1994 | https://conductscience.org/library/papers/8137296 | PubMed |
| 7 | 22149876 | Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22149876 | PubMed |
| 8 | 20125090 | Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. | Nat Rev Clin Oncol | 2010 | https://conductscience.org/library/papers/20125090 | PubMed |
| 9 | 26977878 | Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. | Cancer Cell | 2016 | https://conductscience.org/library/papers/26977878 | PubMed |
| 10 | 22114931 | Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. | Breast Cancer Res | 2011 | https://conductscience.org/library/papers/22114931 | PubMed |
| 11 | 326386 | Current status of estrogen and progesterone receptors in breast cancer. | Cancer | 1977 | https://conductscience.org/library/papers/326386 | PubMed |
| 12 | 28968163 | MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28968163 | PubMed |
| 13 | 24807915 | Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification? | Oncologist | 2014 | https://conductscience.org/library/papers/24807915 | PubMed |
| 14 | 24185512 | ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. | Nat Genet | 2013 | https://conductscience.org/library/papers/24185512 | PubMed |
| 15 | 25002028 | CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. | Cancer Cell | 2014 | https://conductscience.org/library/papers/25002028 | PubMed |
| 16 | 16291983 | Distinct sets of genetic alterations in melanoma. | N Engl J Med | 2005 | https://conductscience.org/library/papers/16291983 | PubMed |
| 17 | 10473088 | Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. | Clin Cancer Res | 1999 | https://conductscience.org/library/papers/10473088 | PubMed |
| 18 | 27717303 | Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27717303 | PubMed |
| 19 | 27801670 | Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor. | Oncotarget | 2016 | https://conductscience.org/library/papers/27801670 | PubMed |
| 20 | 18316794 | Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18316794 | PubMed |
Cited by27
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 36 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42573210 | miR-640 Enhances Abemaciclib Sensitivity by Suppressing CDK Inhibitor Resistance-Associated Genes in Breast Cancer Cells. | J Cell Mol Med | 2026 | https://conductscience.org/library/papers/42573210 | PubMed |
| 42073594 | Real-World Outcomes of Palbociclib with Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: A Retrospective Study from Saudi Arabia. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42073594 | PubMed |
| 40110795 | Insulin-like growth factor 2 as a driving force for exponential expansion and differentiation of the neonatal thymus. | Development | 2025 | https://conductscience.org/library/papers/40110795 | PubMed |
| 39810652 | Real-world study of patients with HR+/ HER2- metastatic breast cancer treated with palbociclib and fulvestrant. | Future Oncol | 2025 | https://conductscience.org/library/papers/39810652 | PubMed |
| 39330025 | Therapeutic Prospects of Abemaciclib for Patients with Endometrial Cancer. | Curr Oncol | 2024 | https://conductscience.org/library/papers/39330025 | PubMed |
| 37889120 | Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer. | Clin Cancer Res | 2024 | https://conductscience.org/library/papers/37889120 | PubMed |
| 37567880 | Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer. | NPJ Breast Cancer | 2023 | https://conductscience.org/library/papers/37567880 | PubMed |
| 37384539 | Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers. | Cancer Res | 2023 | https://conductscience.org/library/papers/37384539 | PubMed |
| 36792625 | Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models. | Sci Rep | 2023 | https://conductscience.org/library/papers/36792625 | PubMed |
| 36153348 | Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer. | NPJ Precis Oncol | 2022 | https://conductscience.org/library/papers/36153348 | PubMed |
| 35582612 | Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem. | Cancer Drug Resist | 2020 | https://conductscience.org/library/papers/35582612 | PubMed |
| 35133007 | Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study. | Int J Cancer | 2022 | https://conductscience.org/library/papers/35133007 | PubMed |
| 34999182 | Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response. | Pharmacol Ther | 2022 | https://conductscience.org/library/papers/34999182 | PubMed |
| 34944934 | Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34944934 | PubMed |
| 33452764 | Exploring the five different genes associated with PKCα in bladder cancer based on gene expression microarray. | J Cell Mol Med | 2021 | https://conductscience.org/library/papers/33452764 | PubMed |
| 33353132 | Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series. | J Pers Med | 2020 | https://conductscience.org/library/papers/33353132 | PubMed |
| 33332933 | Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL). | Cancer Res Treat | 2021 | https://conductscience.org/library/papers/33332933 | PubMed |
| 32907621 | Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. | Genome Med | 2020 | https://conductscience.org/library/papers/32907621 | PubMed |
| 32833070 | Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies? | Arch Gynecol Obstet | 2020 | https://conductscience.org/library/papers/32833070 | PubMed |
| 32691623 | Inhibition of CDK2/CyclinE1 by xanthones from the mangosteen (Garcinia mangostana): a structure-activity relationship study. | Nat Prod Res | 2021 | https://conductscience.org/library/papers/32691623 | PubMed |
Genes29
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30167331
GET https://conductscience.org/api/papers/v1/30167331/references?page=2